SAT-119 Targeting Glutamate Metabolism and Signaling in ER+, Endocrine Therapy-Resistant Breast Cancer

Estrogen receptor-positive (ER+) breast cancer is the most commonly diagnosed form of this malignancy. Aromatase inhibitors and selective estrogen receptor modulators or degraders (SERMS, SERDs) can be highly effective in treating ER+ breast cancer, but de novo and acquired resistance to these inter...

Descripción completa

Detalles Bibliográficos
Autores principales: Olukoya, Ayodeji O, Stires, Hillary, Guerra, Yanira, Persaud, Sonali, Ma, Shihong, Raj, Ganesh V, Riggins, Rebecca B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Tumor Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207534/
http://dx.doi.org/10.1210/jendso/bvaa046.1086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207534/
http://dx.doi.org/10.1210/jendso/bvaa046.1086

Ejemplares similares